-+ 0.00%
-+ 0.00%
-+ 0.00%

JP Morgan Maintains Overweight on Lexeo Therapeutics, Lowers Price Target to $10

Benzinga·05/30/2025 14:58:20
Listen to the news
JP Morgan analyst Tessa Romero maintains Lexeo Therapeutics (NASDAQ:LXEO) with a Overweight and lowers the price target from $16 to $10.